These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 29105343)

  • 1. Racial disparity in utilization of therapeutic modalities among multiple myeloma patients: a SEER-medicare analysis.
    Ailawadhi S; Frank RD; Advani P; Swaika A; Temkit M; Menghani R; Sharma M; Meghji Z; Paulus S; Khera N; Hashmi SK; Paulus A; Kakar TS; Hodge DO; Colibaseanu DT; Vizzini MR; Roy V; Colon-Otero G; Chanan-Khan AA
    Cancer Med; 2017 Dec; 6(12):2876-2885. PubMed ID: 29105343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trends in multiple myeloma presentation, management, cost of care, and outcomes in the Medicare population: A comprehensive look at racial disparities.
    Ailawadhi S; Frank RD; Sharma M; Menghani R; Temkit M; Paulus S; Khera N; Hashmi S; Advani P; Swaika A; Paulus A; Aslam N; Sher T; Roy V; Colon-Otero G; Chanan-Khan A
    Cancer; 2018 Apr; 124(8):1710-1721. PubMed ID: 29360160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Racial disparities in treatment use for multiple myeloma.
    Fiala MA; Wildes TM
    Cancer; 2017 May; 123(9):1590-1596. PubMed ID: 28085188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subsidies for Oral Chemotherapy and Use of Immunomodulatory Drugs Among Medicare Beneficiaries With Myeloma.
    Olszewski AJ; Dusetzina SB; Eaton CB; Davidoff AJ; Trivedi AN
    J Clin Oncol; 2017 Oct; 35(29):3306-3314. PubMed ID: 28541791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival Trends in Young Patients With Multiple Myeloma: A Focus on Racial-Ethnic Minorities.
    Ailawadhi S; Azzouqa AG; Hodge D; Cochuyt J; Jani P; Ahmed S; Sher T; Roy V; Ailawadhi M; Alegria VR; Manochakian R; Vishnu P; Grover A; Abdulazeez MF; Paulus A; Chanan-Khan A
    Clin Lymphoma Myeloma Leuk; 2019 Oct; 19(10):619-623. PubMed ID: 31377212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple myeloma treatment transformed: a population-based study of changes in initial management approaches in the United States.
    Warren JL; Harlan LC; Stevens J; Little RF; Abel GA
    J Clin Oncol; 2013 Jun; 31(16):1984-9. PubMed ID: 23569317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.
    Durie BGM; Hoering A; Abidi MH; Rajkumar SV; Epstein J; Kahanic SP; Thakuri M; Reu F; Reynolds CM; Sexton R; Orlowski RZ; Barlogie B; Dispenzieri A
    Lancet; 2017 Feb; 389(10068):519-527. PubMed ID: 28017406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of access to NCI- and NCCN-designated cancer centers on outcomes for multiple myeloma patients: A SEER registry analysis.
    Ailawadhi S; Advani P; Yang D; Ghosh R; Swaika A; Roy V; Foran J; Colon-Otero G; Chanan-Khan A
    Cancer; 2016 Feb; 122(4):618-25. PubMed ID: 26565660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Racial and Ethnic Disparities in Utilization Rate, Hospital Volume, and Perioperative Outcomes After Total Knee Arthroplasty.
    Zhang W; Lyman S; Boutin-Foster C; Parks ML; Pan TJ; Lan A; Ma Y
    J Bone Joint Surg Am; 2016 Aug; 98(15):1243-52. PubMed ID: 27489314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Racial disparities in treatment patterns and outcomes among patients with multiple myeloma: a SEER-Medicare analysis.
    Ailawadhi S; Parikh K; Abouzaid S; Zhou Z; Tang W; Clancy Z; Cheung C; Zhou ZY; Xie J
    Blood Adv; 2019 Oct; 3(20):2986-2994. PubMed ID: 31648322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Racial Disparities in the Utilization of Novel Agents for Frontline Treatment of Multiple Myeloma.
    Fiala MA; Wildes TM; Vij R
    Clin Lymphoma Myeloma Leuk; 2020 Oct; 20(10):647-651. PubMed ID: 32522440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Racial/ethnic differences in survival among elderly patients with a primary glioblastoma.
    Barnholtz-Sloan JS; Maldonado JL; Williams VL; Curry WT; Rodkey EA; Barker FG; Sloan AE
    J Neurooncol; 2007 Nov; 85(2):171-80. PubMed ID: 17530174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment Patterns and Clinical and Economic Outcomes in Patients With Newly Diagnosed Multiple Myeloma Treated With Lenalidomide- and/or Bortezomib-containing Regimens Without Stem Cell Transplant in a Real-world Setting.
    Chari A; Parikh K; Ni Q; Abouzaid S
    Clin Lymphoma Myeloma Leuk; 2019 Oct; 19(10):645-655. PubMed ID: 31377207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disparities in Utilization of Autologous Stem Cell Transplantation as Consolidative Therapy for Multiple Myeloma: A Single Institution Retrospective Review.
    Lupak O; Xiaoxia H; Xie P; Thanikachalam K; Jabbour-Aida H; Farhan S; Emole J
    Clin Lymphoma Myeloma Leuk; 2021 Aug; 21(8):e680-e685. PubMed ID: 34148850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Racial Differences in the Surgical Care of Medicare Beneficiaries With Localized Prostate Cancer.
    Schmid M; Meyer CP; Reznor G; Choueiri TK; Hanske J; Sammon JD; Abdollah F; Chun FK; Kibel AS; Tucker-Seeley RD; Kantoff PW; Lipsitz SR; Menon M; Nguyen PL; Trinh QD
    JAMA Oncol; 2016 Jan; 2(1):85-93. PubMed ID: 26502115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnosis and therapy of multiple myeloma.
    Palumbo A; Cerrato C
    Korean J Intern Med; 2013 May; 28(3):263-73. PubMed ID: 23682217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma.
    Laubach JP; Schlossman RL; Mitsiades CS; Anderson KC; Richardson PG
    Expert Rev Hematol; 2011 Feb; 4(1):51-60. PubMed ID: 21322778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prescription Drug Coverage and Outcomes of Myeloma Therapy Among Medicare Beneficiaries.
    Olszewski AJ; Dusetzina SB; Trivedi AN; Davidoff AJ
    J Clin Oncol; 2018 Oct; 36(28):2879-2886. PubMed ID: 30113885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [First-line treatment of multiple myeloma].
    Breitkreutz I; Raab M; Goldschmidt H
    Internist (Berl); 2019 Jan; 60(1):23-33. PubMed ID: 30552458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The emerging role of novel therapies for the treatment of relapsed myeloma.
    Richardson PG; Hideshima T; Mitsiades C; Anderson KC
    J Natl Compr Canc Netw; 2007 Feb; 5(2):149-62. PubMed ID: 17335684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.